BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34474414)

  • 1. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.
    Blazejak C; Stranzenbach R; Gosman J; Gambichler T; Wehkamp U; Stendel S; Klemke CD; Wobser M; Olk J; Nicolay JP; Weyermann M; Stadler R; Assaf C
    Dermatology; 2022; 238(3):498-506. PubMed ID: 34474414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
    Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.
    Jidar K; Ingen-Housz-Oro S; Beylot-Barry M; Paul C; Chaoui D; Sigal-Grinberg M; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2009 Sep; 161(3):660-3. PubMed ID: 19438862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
    Di Raimondo C; Vaccarini S; Nunzi A; Rapisarda V; Zizzari A; Meconi F; Monopoli A; Narducci MG; Scala E; Bianchi L; Tesei C; Cantonetti M
    Dermatol Ther; 2022 Jun; 35(6):e15482. PubMed ID: 35373414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
    Masuzawa M; Takasu H; Amoh Y
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2451-5. PubMed ID: 26809303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
    Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
    Cancer; 2005 Dec; 104(11):2437-41. PubMed ID: 16216001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.
    Pellegrini C; Stefoni V; Casadei B; Maglie R; Argnani L; Zinzani PL
    Ann Hematol; 2014 Nov; 93(11):1853-7. PubMed ID: 24908331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
    Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
    J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
    Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
    Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.
    Affandi AM; Blumetti TP; Wells J; Hertzberg M; Fernandez-Peñas P
    Australas J Dermatol; 2015 Nov; 56(4):294-7. PubMed ID: 25496219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acitretin for the treatment of cutaneous T-cell lymphoma.
    Cheeley J; Sahn RE; DeLong LK; Parker SR
    J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.
    Buhl T; Bertsch HP; Kaune KM; Mitteldorf C; Schön MP; Kretschmer L
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):E21-4. PubMed ID: 19858049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
    Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
    Kim EJ; Mangold AR; DeSimone JA; Wong HK; Seminario-Vidal L; Guitart J; Appel J; Geskin L; Lain E; Korman NJ; Zeitouni N; Nikbakht N; Dawes K; Akilov O; Carter J; Shinohara M; Kuzel TM; Piette W; Bhatia N; Musiek A; Pariser D; Kim YH; Elston D; Boh E; Duvic M; Huen A; Pacheco T; Zwerner JP; Lee ST; Girardi M; Querfeld C; Bohjanen K; Olsen E; Wood GS; Rumage A; Donini O; Haulenbeek A; Schaber CJ; Straube R; Pullion C; Rook AH; Poligone B
    JAMA Dermatol; 2022 Sep; 158(9):1031-1039. PubMed ID: 35857290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.